WO1999062502A3 - Methods for the normalization of sexual response and amelioration of long term genital tissue degradation - Google Patents

Methods for the normalization of sexual response and amelioration of long term genital tissue degradation Download PDF

Info

Publication number
WO1999062502A3
WO1999062502A3 PCT/CA1999/000508 CA9900508W WO9962502A3 WO 1999062502 A3 WO1999062502 A3 WO 1999062502A3 CA 9900508 W CA9900508 W CA 9900508W WO 9962502 A3 WO9962502 A3 WO 9962502A3
Authority
WO
WIPO (PCT)
Prior art keywords
sexual response
amelioration
normalization
methods
tissue degradation
Prior art date
Application number
PCT/CA1999/000508
Other languages
French (fr)
Other versions
WO1999062502A2 (en
Inventor
Jeremy P W Heaton
Michael A Adams
Original Assignee
Univ Kingston
Jeremy P W Heaton
Michael A Adams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kingston, Jeremy P W Heaton, Michael A Adams filed Critical Univ Kingston
Priority to DE69931487T priority Critical patent/DE69931487T2/en
Priority to EP99923347A priority patent/EP1082118B1/en
Priority to AU40272/99A priority patent/AU764009B2/en
Priority to CA002331387A priority patent/CA2331387A1/en
Publication of WO1999062502A2 publication Critical patent/WO1999062502A2/en
Publication of WO1999062502A3 publication Critical patent/WO1999062502A3/en
Priority to HK01106459A priority patent/HK1037517A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Abstract

The present invention provides, in one embodiment, a method of normalizing the timing of sexual response in a mammal comprising the administration of an amount of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective vasocongestive arousal. In an alternative embodiment, the present invention provides a method for the prophylactic treatment of long-term tissue degradation in the genital organs comprising the administration to a mammal of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective vasocongestive arousal. The preferred central nervous system sexual response initiator is apomorphine or a pharmaceutically acceptable acid addition salt thereof.
PCT/CA1999/000508 1998-05-29 1999-05-28 Methods for the normalization of sexual response and amelioration of long term genital tissue degradation WO1999062502A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE69931487T DE69931487T2 (en) 1998-05-29 1999-05-28 USE OF APOMORPHIN FOR THE TREATMENT OF PREMATURE EJACULATION
EP99923347A EP1082118B1 (en) 1998-05-29 1999-05-28 Use of apomorphine in the treatment of premature ejaculation
AU40272/99A AU764009B2 (en) 1998-05-29 1999-05-28 Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
CA002331387A CA2331387A1 (en) 1998-05-29 1999-05-28 Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
HK01106459A HK1037517A1 (en) 1998-05-29 2001-09-12 Use of apomorphine in the treatment of premature ejaculation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/086,630 1998-05-29
US09/086,630 US6403605B1 (en) 1998-05-29 1998-05-29 Methods for the normalization of sexual response and amelioration of long term genital tissue degradation

Publications (2)

Publication Number Publication Date
WO1999062502A2 WO1999062502A2 (en) 1999-12-09
WO1999062502A3 true WO1999062502A3 (en) 2000-06-15

Family

ID=22199842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000508 WO1999062502A2 (en) 1998-05-29 1999-05-28 Methods for the normalization of sexual response and amelioration of long term genital tissue degradation

Country Status (11)

Country Link
US (3) US6403605B1 (en)
EP (2) EP1082118B1 (en)
AR (1) AR019579A1 (en)
AT (1) ATE326969T1 (en)
AU (1) AU764009B2 (en)
CA (1) CA2331387A1 (en)
DE (1) DE69931487T2 (en)
ES (1) ES2268869T3 (en)
HK (1) HK1037517A1 (en)
TW (1) TWI232748B (en)
WO (1) WO1999062502A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
SE0002934D0 (en) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (en) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
WO2004089374A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
PT1750766E (en) 2004-05-11 2013-09-30 Emotional Brain Bv Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
SG174079A1 (en) * 2007-02-12 2011-09-29 Dmi Biosciences Inc Treatment of comorbid premature ejaculation and erectile dysfunction
AU2008216363B2 (en) * 2007-02-12 2014-05-08 Aytu Bioscience, Inc. Reducing side effects of tramadol
EP2328530A4 (en) * 2008-08-22 2012-09-12 Us Worldmeds Llc Transdermal delivery of apomorphine using microneedles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004621A1 (en) * 1986-02-04 1987-08-13 Ekkehard Othmer Treatment of sexual dysfunction with buspirone
WO1995028930A1 (en) * 1994-04-22 1995-11-02 Pentech Pharmaceuticals, Inc. Dosage forms and method for ameliorating male erectile dysfunction
EP0714663A2 (en) * 1994-11-28 1996-06-05 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
WO1997013770A1 (en) * 1995-10-13 1997-04-17 Neurosearch A/S 8-azabicyclo[3.2.1]oct-2-ene derivatives, their preparation and use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4687773A (en) 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US4980358A (en) * 1988-04-04 1990-12-25 George D. McAdory Method employing gonadal hormones and dopamine agonist intended for combined use in the improvement of lymphocyte function
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
DE69434304T2 (en) 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmaceutical compositions for the intranasal administration of dihydroergotamine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004621A1 (en) * 1986-02-04 1987-08-13 Ekkehard Othmer Treatment of sexual dysfunction with buspirone
WO1995028930A1 (en) * 1994-04-22 1995-11-02 Pentech Pharmaceuticals, Inc. Dosage forms and method for ameliorating male erectile dysfunction
EP0714663A2 (en) * 1994-11-28 1996-06-05 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
WO1997013770A1 (en) * 1995-10-13 1997-04-17 Neurosearch A/S 8-azabicyclo[3.2.1]oct-2-ene derivatives, their preparation and use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GOLDSTEIN I. ET AL: "Vasculogenic female sexual dysfunction: Vaginal engorgement and clitoral erectile insufficiency syndromes", INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 10/SUPPL. 2 (S84-S90), United Kingdom, XP000853842 *
HEATON JP ET AL: "Effects of castration and exogenous testosterone supplementation in an animal model of penile erection.", J UROL, MAR 1994, 151 (3) P797-800, UNITED STATES, XP000853844 *
HEATON, J.P.W. ET AL: "Recovery of erectile dysfunction by the oral administration of apomorphine", UROLOGY, vol. 45, no. 2, 1995, pages 200 - 206, XP002123417 *
LAL S ET AL: "Apomorphine-induced penile tumescence in impotent patients--preliminary findings.", PROG NEUROPSYCHOPHARMACOL BIOL PSYCHIATRY, 1987, 11 (2-3) P235-42, ENGLAND, XP000853707 *
SEGRAVES R.T.: "Editorial: Pharmacological era in the treatment of sexual disorders", JOURNAL OF SEX AND MARITAL THERAPY, vol. 24, no. 2, 1998, United States, pages 67 - 68, XP000853789 *

Also Published As

Publication number Publication date
ATE326969T1 (en) 2006-06-15
TWI232748B (en) 2005-05-21
AU764009B2 (en) 2003-08-07
EP1082118A2 (en) 2001-03-14
ES2268869T3 (en) 2007-03-16
CA2331387A1 (en) 1999-12-09
AU4027299A (en) 1999-12-20
US6403605B1 (en) 2002-06-11
EP1082118B1 (en) 2006-05-24
DE69931487T2 (en) 2007-05-03
US20030092725A1 (en) 2003-05-15
EP1666040A1 (en) 2006-06-07
US20060281752A1 (en) 2006-12-14
WO1999062502A2 (en) 1999-12-09
HK1037517A1 (en) 2002-02-15
DE69931487D1 (en) 2006-06-29
AR019579A1 (en) 2002-02-27

Similar Documents

Publication Publication Date Title
WO1999062502A3 (en) Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
WO1998044893A3 (en) Method and formulation for treating vascular disease
WO2000038672A3 (en) Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
WO2005051479A3 (en) Electrical stimulation system and method for treating tinnitus
CA2383785A1 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2003020202A3 (en) Method for reducing hypertension and heart failure
CA2255652A1 (en) Isobutylgaba and its derivatives for the treatment of pain
WO1999045920A3 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
CA2213339A1 (en) Method of treating adenosine depletion
AU2604301A (en) Tnf inhibitors for the treatment of neurological, retinal and muscular disorders
EP1381276A4 (en) Method of treating or retarding the development of blindness
WO2000002546A3 (en) Use of caba-analogues for treating insomnia
CA2379752A1 (en) Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients
AU2001278981A1 (en) Prevention and treatment of sexual arousal disorders
WO2000066098A3 (en) Vitamin d derivatives for the treatment of systemic lupus erythematosus
WO2002013804A3 (en) Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid
EP0287204A3 (en) Silver sulfadiazine useful for inhibiting the transmission of the aids virus
WO2002013805A3 (en) Method of treating neurodegenerative disorders of the retina and optic nerve head
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
WO2003024445A1 (en) Drugs comprising combination of antithrombotic agent with pyrazolone derivative
WO1996036339A3 (en) Use of dihydrotestosterone compounds for treating male sexual dysfunction
WO2001042205A3 (en) Treatment of inflammatory bowel disease with vitamin d compounds
HK1025894A1 (en) Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release.
WO2000066097A3 (en) Use of nicorandil in treatment of sexual dysfunctions or for enhancement of sexual functions
AU1564500A (en) Method for obtaining and using a combination of a purine and a nitrogen monoxidedonor for preventing or treating sexual dysfunction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2331387

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 40272/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999923347

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999923347

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 40272/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999923347

Country of ref document: EP